Open AccessPlasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint
Author(s) -
Leila B. Giron,
Emmanouil Papasavvas,
Livio Azzoni,
Xiangfan Yin,
Alitzel Anzurez,
Mohammad Damra,
Karam Mounzer,
Jay R. Kostman,
Ian Sanne,
Cynthia Firnhaber,
Hiroaki Tateno,
Qin Liu,
Luis J. Montaner,
Mohamed AbdelMohsen
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002476
Subject(s) - setpoint , human immunodeficiency virus (hiv) , antibody , virology , immunology , medicine , computer science , artificial intelligence
HIV cure research urgently needs to identify pre-analytic treatment interruption (ATI) biomarkers of time-to-viral-rebound and viral setpoint to mitigate the risk of ATI and accelerate development of a cure. We previously reported that galactosylated IgG glycans, G2, negatively correlate with cell-associated HIV DNA and RNA during antiretroviral therapy (ART). We hypothesized that this and other plasma glycomic traits can predict time-to-viral-rebound and viral setpoint upon ART cessation.